Adempas is approved to treat adults with pulmonary arterial hypertension (PAH) (WHO Group 1). The Adempas clinical studies included mostly patients with WHO functional class II-III symptoms. It is not known if Adempas is safe and effective in children.
WHO=World Health Organization
How far might Adempas take you?
Adempas has been shown to help increase the ability to walk farther (measured by a 6-minute walk distance [6MWD] test), improve some PAH symptoms, and help slow down the worsening of a patient’s physical condition. A 6MWD test determines how far patients can walk in 6 minutes. Doctors may use it periodically to measure progress.
Worsening of physical condition includes death, heart/lung transplant, a surgery to reduce pressure in the lung, hospitalization for worsening of pulmonary hypertension (PH), start of a new PAH-specific treatment, continued decline in the ability to exercise (measured by a 6MWD test) and some PAH symptoms.
CHANGE IN 6MWD AT THE END OF 12 WEEKS
A 12-week study of 443 adults with PAH (WHO Group 1) showed that patients who took Adempas walked farther during the 6MWD test, compared to patients who did not take Adempas.
50% more patients who took Adempas improved their WHO functional class compared to patients who took a placebo (no Adempas).
21% of Adempas patients showed WHO functional class improvement vs 14% of placebo patients.
Q+A: Patient Perspective
Ask your doctor if you have questions about Adempas. Below, watch one patient share part of his experience of treating PAH with Adempas.
SINCE I STARTED ADEMPAS